logo-loader

MGC Pharmaceuticals get set for LSE debut as first medicinal cannabis company listed on main market

Published: 10:08 05 Feb 2021 GMT

MGC Pharmaceuticals Ltd's (ASX:MXC) (FRA:H5O) (LON:MXC) Co-founder and MD Roby Zomer joins Proactive London to explain why the company has chosen to list on the London Stock Exchange (LSE) on Tuesday, February 9. 

This move will mean the firm will become the first medicinal cannabis company to be admitted to the main market. 

This follows a strongly supported £6.5 million share placement led by leading UK institutional fund managers and supported by UK family office and professional high net worth investors.

MGC Pharmaceuticals reveals strategic objectives for H1 2024

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) CEO and Managing Director Roby Zomer speaks to Thomas Warner from Proactive London following the completion of a share consolidation and capital raise. With these restructuring initiatives completed, Zomer shares his enthusiasm for the...

on 13/11/23